Aurora Cannabis: The Market Prices Decline. The Balance Sheet Says Otherwise.

The market is still pricing Aurora Cannabis as a company falling apart. Revenue down 9%, adjusted EBITDA slashed from CAD 10.8 million to CAD 3.4 million, free cash flow flipping negative. The headlines from the Q1 FY2027 results, released August 5, read like a business in retreat.

The cash-flow path says something different. The worst of the headwinds is already in the numbers, the balance sheet is sitting on nearly CAD 195 million in effective liquidity, there is zero debt, and the international medical business — the higher-margin core the company has been building for three years — grew 17% in a quarter that saw everything else get hammered. The market cap is CAD 185 million. The company's net cash position is bigger than the business itself.

That is the dislocation. Not a recovery story. Not a comeback narrative. A balance sheet and a growing international segment that look hard to dismiss even if you don't love the space.

What happened in Q1

Total net revenue was CAD 67.6 million, down 9% from the year-ago quarter. But the breakdown matters more than the headline.

International medical cannabis revenue rose 17% to CAD 43.3 million, now 64% of total revenue versus 50% a year earlier. The growth came from Germany, where Aurora holds a top-tier market share and patient demand is expanding. Canada's medical segment fell 25% to CAD 20.7 million, driven by a 30% cut in the federal Veterans Affairs reimbursement rate that took effect April 1 — from CAD 8.50 per gram down to CAD 6.00. That is a one-time pricing shock, not a demand collapse. Patient eligibility and behavior were unchanged, per management.

The consumer cannabis tail shrank to CAD 2.1 million, down from CAD 7.9 million a year earlier, as Aurora continues winding down the low-margin recreational business. Consumer adjusted gross margin was 20%, compared to 61% for medical. Stripping the low-margin tail while the high-margin core grows is supposed to improve the economics over time.

Adjusted EBITDA fell to CAD 3.4 million from CAD 10.8 million. The drop is almost entirely explained by the reimbursement cut and the consumer wind-down — both are known, priced, and directional. Adjusted net income came in at CAD 3.8 million, down from CAD 6.6 million, but the GAAP net loss improved sharply to CAD 4.0 million from CAD 10.2 million, driven by higher fair-value gains on biological assets and lower operating expenses. Free cash flow was an outflow of CAD 5.8 million versus an inflow of CAD 6.8 million a year earlier. That is the number to watch most closely — the business burned cash in Q1 and burned CAD 14.3 million for all of FY2026, which means the cash-generation story is not yet proven.

The thing the market hasn't felt yet

Aurora is trading at CAD 2.99, a market cap of roughly CAD 185 million on 61.9 million shares. Cash and short-term investments sit at CAD 149 million. An additional CAD 46.4 million is expected to be released from an insurance program. That puts effective liquidity near CAD 195 million. With zero debt, the company's net cash exceeds its market cap. The current ratio is 5.94. This is not a company on the verge of dilution or distress.

Compare that to what the market is pricing. At current levels, Aurora trades at roughly 6x the CAD 28.7 million in adjusted EBITDA that street estimates project for FY2027. That multiple assumes the business stays flat and never proves it can be a cash generator. It prices in permanent decline in a business whose international segment grew 17% in the quarter and whose Safari Flower acquisition just added EU-GMP-certified manufacturing capacity that management said is already accretive to adjusted EBITDA.

The Safari deal matters more than the press release makes it sound. The constraint on international growth for EU medical cannabis producers isn't demand — it's GMP-certified manufacturing capacity. Aurora now operates a 59,000-square-foot certified facility in Ontario, on top of its own German production at Leuna, which is nearing a capacity doubling. The company plans to invest CAD 3.5 million over three years in Safari's growth improvements. That is a small spend to unlock incremental supply for Germany, Poland, the UK, and potentially beyond.

The 12-month bridge

Here is what needs to get better. Management expects Q2 revenue and adjusted EBITDA to improve sequentially from Q1. The VAC reimbursement cut was a one-quarter shock — it hit the April-June quarter in full, and there is no reason to expect another cut of similar magnitude in the near term. International growth in Germany and Poland should continue to offset the lower Canadian base.

Full-year FY2027 guidance calls for revenue at or near FY2025 levels, with adjusted gross margins in the mid-to-high 50s. Street estimates project FY2027 adjusted EBITDA around CAD 28.7 million, roughly half of FY2026's record CAD 53.8 million. If you accept that FY2027 is a trough year — the reimbursement cut hits, the consumer business disappears, and international growth offsets the decline — then FY2028 is where the math starts to work again. International revenue grew 29% for all of FY2026. If that trajectory holds and the domestic medical base stabilizes at lower reimbursement rates, adjusted EBITDA in the CAD 35-40 million range for FY2028 is achievable, not speculative.

Simple forward multiples beat complex models here. A CAD 35-40 million EBITDA business with no debt, CAD 195 million in liquidity, and leading positions in multiple European medical markets is worth more than 6x the reduced FY2027 trough. An 8x multiple on a CAD 38 million EBITDA mid-point implies CAD 304 million in enterprise value — or roughly CAD 4.90 per share on today's share count. That is a 64% gain from current levels.

The target assumes the international growth holds and free cash flow returns to positive territory. If management can get FCF back to even breakeven by FY2028, the dilution risk drops to near zero and the balance sheet becomes an active tailwind rather than a passive cushion.

What could still break the setup

Germany is the primary risk. Aurora holds leading market share there, but pricing pressure is intensifying in the value segment as new competitors enter. The company is managing this by shifting mix toward core and premium products, but sustained margin erosion would eat the international growth thesis. There is also regulatory uncertainty — the German government has been discussing tighter rules on online medical cannabis prescriptions. If access constricts, demand growth slows.

Free cash flow is the second risk. The business burned cash in Q1 and for all of FY2026. Street projects negative FCF of approximately CAD 6.3 million in FY2027. If cash burn persists into FY2028, the dilution that has already grown the share count by 21% since 2023 could resume. That would be the clearest sign the operating improvements are not translating into actual cash.

And the cannabis sector itself carries a reputation risk that has nothing to do with Aurora's numbers. The broader space has been a multi-year loser. If investor appetite for cannabis equities remains dead, even a genuinely improving business can stay cheap. But that dynamic cuts both ways — it is also what creates the entry.

The action

This is not a story about excitement. It is about a business whose worst-known-quarter (Q1, with the full impact of the VAC cut and consumer wind-down) is now in the rearview, whose international segment continues growing, and whose net cash position exceeds its market capitalization. The setup is a balance sheet and a growing revenue stream that look hard to dismiss at the price.

I'd enter a position here and let the Q2 sequential improvement either confirm or weaken the bridge. If Q2 doesn't beat Q1 on both revenue and EBITDA — or if Germany's regulatory environment tightens in a way that meaningfully slows growth — the setup resets and the thesis needs rethinking. Discipline over ego.

Target: CAD 4.90 per share. Timeframe: 12-18 months, contingent on FY2027 trough clearing and international growth holding. Tripwire: failure to show sequential Q2 improvement, or a second consecutive year of negative free cash flow that forces share issuance.